Cy Aaron Stein, M.D., Ph.D.
- Professor, Department of Medical Oncology & Therapeutics Research
Cy Aaron Stein, M.D., Ph.D.
- Medical Oncology
- Urology and Urologic Oncology
- Prostate Cancer
“The relief of human suffering and anxiety may be the most satisfying long-term thing a human being can do.”
Named a “Super Doctor” by The New York Times Magazine, and one of L.A's Top Doctors by Pasadena Magazine, Cy Aaron Stein, M.D., Ph.D. has collected many superlatives over his 30-year career.
Specializing in urology and prostate cancer, Dr. Stein is a sought-after expert whose authored hundreds of scholarly papers and several medical texts including Molecular Medicine and The Prostate Cancer Book. He also holds 11 patents. Yet his Number One advice to fellow physicians is, “Never think about yourself. It's only about the patient.”
Dr. Stein earned his medical degree at New York's Albert Einstein College of Medicine, which he followed with a three-year assignment at the National Cancer Institute in Bethesda, MD. Returning to New York, he spent the next two decades establishing himself as a foremost physician and educator at Einstein, Montefiore Medical Center and Columbia University. He joined City of Hope in 2012.
Outside the office, Dr. Stein channels his creative energy into writing historical fiction. His novel, The Medicus Codex, is told from the perspective of a Judean physician in Ancient Rome.
- 1982, Albert Einstein College of Medicine (AECOM) Bronx, NY, Awarded M.D.
- 1978, Stanford University, Stanford, CA, Ph.D., Organic Chemistry
- 1974, Brown University, Providence, RI, B.A
- 1985 - 1988, National Cancer Institute, Bethesda, Maryland
- 1983 -1985, Internal medicine resident, The New York Hospital-Cornell Medical Center, New York, NY
- 1982 -1983, Internal medicine intern, The New York Hospital-Cornell Medical Center, New York, NY
- California Medical License
- Maryland Medical License
- New York State Medical License
- 1986, Diplomate, American Board of Internal Medicine
- 1987, Diplomate, American Board of Oncology
September 18, 2014
March 28, 2014
February 09, 2014
January 30, 2014
January 20, 2014
January 17, 2014
November 30, 2013
September 05, 2013
September 03, 2013
September 01, 2013
March 17, 2013
February 22, 2013
February 22, 2013
January 10, 2013
December 28, 2012
November 13, 2012
Liu, W., Bulgaru, A., Haigentz, M., Stein, C.A., Perez-Soler, R., and Mani, S. The bcl- 2-family of protein ligands as cancer drugs: The next generation of therapuetics. Curr. Med. Chem.-Anti-Cancer Agents, 2003 (3), 217-223.
Nichols, G. and Stein, C.A. "Modulation of the activity of bcl-2 in Waldenstrom's Macroglobulinemia using antisense oligonucleotides" Semin. Oncol. 2003, (30) 297-299.
Wang, L., Prakash, R., Stein, C.A., Koehn, R., and Ruffner, D. "Progress in the Delivery of Therapeutic Oligonucleotides: Organ/cellular Distribution and Targeted Delivery of Oligonucleotides In Vivo", Antisense and Nucleic Acid Drug Development, 2003 (13) 169-189.
Cho-Chung, Y., Gewirtz, A., and Stein, C.A. (eds). Therapeutic Oligonucleotides. Ann. NY Acad Sci., 2003 (1002).; Stein, C.A., Dias, N., Benimetskaya, L, Jepsen, J., Lai, J., and Raffo, A. "LY900003 (Isis 3521) and G3139 (Genasense; Oblimersen)-Phosphorothioate Antisense Oligonucleotides With Pleotropic Mechanisms of Action." Nucleic Acid Therapeutics in Cancer, A. Gewirtz, ed., 2004, 171-191.
Stein, C.A., Mani, S., Benimetskaya, L. "Combinations of Chemotherapy with Antisense Approaches Against bcl-2", in Combination Cancer Therapy: Modulators and Potentiators, G., Schwartz, ed., Humana Press, 2005, p. 207-228; Stein, C.A., Benimetskaya, L., and Mani, S. "Antisense Inhibition of Gene Expression", in Principles and Practice of Oncology, 7th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2005, p. 2891-2898.
Stein, C.A. and Rossi, J. "A Critical Assessment of the Potential of Short Interfering RNA Therapeutics', Drug Discovery Today: Technologies, 2005, www.drugdiscoverytoday.com; http://www.sciencedirect.com (2) 27-31.
Cho-Chung, Y., Gewirtz, A., and Stein, C.A. (eds). Therapeutic Oligonucleotides-Transcriptonal and Translational Strategies for Silencing Gene Expression. Ann. NY Acad Sci., 2005 (1058)
Benimetskaya, L., Lai, J., Khvorova, A., Wu, S., Miller, P. and Stein, C.A. "Induction of Apoptosis by G3139 in Melanoma Cells", Ann. NY Acad. Sci, 2005 (1058) 235-245.
Stein, C.A., Benimetskaya, L., and Mani, S. "Antisense Strategies for Oncogene Inactivation", Semin. Oncol. 2005, (32) 563-572.
Kornblum, N., Ayyanar, K., Benimetskaya, L., Richardson, P., Iacobelli, M., and Stein, C.A. "Defibrotide, a Polydisperse Mixture of Single-Stranded Phosphodiester Oligonucleotides with Life-Saving Activity in Severe Hepatic Veno-Occlusive Disease: Clinical Outcomes and Potential Mechanisms of Action", Oligonucleotides, 2006 (16), 105-114.
Stein, C.A. "The Genasense 'Learning Curve'", Letter to the Editor, Nature Biotechnology, 2007 (25) 972-973.; Stein, C.A. "Genasense: It Ain't Over Till the Fat Lady Sings", Editorial, Oligonucleotides, 2007 (17) 345-348.
Stein, C.A. Kornblum, N., Lai, J., and Benimetskaya, L. "Genasense (G3139): An antisense Bcl-2 oligodeoxyribonucleotide with substantial clinical activity and a complex mechanism of action". In Therapeutic Oligonucleotides, J. Kurreck, ed., Biomolecular Science, Royal Society of Chemistry, 2008, p. 23-42.
Stein, C.A., Benimetskaya, L., Kornblum, N., and Mani, S. "Antisense Agents", in Principles and Practice of Oncology, 8th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2008.; Stein, C.A., and Colombini, M. "Specific VDAC Inhibitors: Phosphorothioate Oligonucleotides" J. Bioenerg. Biomemb., 2008, 40:157-162.
Stein, C.A., Hoehn, B., and Rossi, J. "Oligonucleotide Therapeutics" In Principles of Anticancer Drug Development, E. Garrett-Mayer, et al., eds. Springer Press, 2011, p. 565-587.
Stein, C.A., and Soifer, H. "Antisense Inhibition of Gene Expression", in Principles and Practice of Oncology, 9th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2011.
Soifer, H., Koch, T., Hansen, B., Hoeg, A., Oerum, H., and Stein, C.A. "Silencing of Gene Expression by Gymnotic Delivery of Antisense Oligonucleotides" in M. Kaufmann and C. Klinger, eds., Functional Genomics: Methods and Protocols: Methods in Molecular Biology, 815:333-346 Springer Press, 2011.
Stein, C.A., and Goel, S. "Therapeutic Oligonucleotides-The Road Not Taken", invited commentary in Clinical Cancer Research, 2011, 17:6369-6372.
Twardowski, P. and Stein, C.A. "Beyond the Abstract-Direct regulation of androgen receptor activity in prostate cancer cells by potent CYP17 inhibitors". UroToday.com, July 2, 2012
Hu, J., Hsu, J., Bergerot, P., Yuh, B., Stein, C.A., and Pal, S. "Preoperative therapy for localized prostate cancer: A comprehensive overview", Maturitas, 2013, 74:3-9.
Pal, S., Stein, CA, Sartor, O. "Enzalutamide for the treatment of prostate cancer," Expert Opinion in Pharmacotherapy, 2013, (14), 679-685
Eroglu, Z., Stein, C.A., Pal, S. "Targeting angiopoietin-2 signaling in cancer therapy, Expert Opinion in Investigational Drugs, 2013, (22), 813-825.
- American Society for Clinical Oncology
- American Association for Cancer Research
- American Society for Gene Therapy (Oligonucleotide Therapeutics Committee, 2005-2008)